PAI Pharma acquires Nivagen to boost US injectable drug production

The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing

GSK reports breakthrough results in chronic hepatitis B trials

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies

Alumis reports breakthrough Phase 3 results for oral psoriasis therapy

The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data

Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs

Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments

Valneva and Serum Institute end chikungunya vaccine partnership

Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries

FibroBiologics moves experimental psoriasis therapy into FDA review

The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline

Enveric Biosciences bags key US patent for next-gen neuropsychiatric drugs

The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”